Marc Le Menestrel

New institutional actors for Global Health in Developing Countries

Marc Le Menestrel — 2012-05-07T13:05:32Z

This is a research started by Cristin Fieber from BSM Master in Business. Below are a few tentative sections:

- Students Projects: Ethics and Health

New financing modes for global health in developing countries

Cristin Fieber, Marc Le Menestrel — 2012-05-07T12:54:16Z

This is a research started by Joao Rocha from the BSM Master in Business. More to come in June 2012.

- Students Projects: Ethics and Health

Bibliographic References on New Business Models

Marc Le Menestrel — 2012-02-17T15:14:51Z

Relevant articles on Health Care, Oncology and Social Innovation:

Innovating for More Affordable Health Care (2011). Stanford Social Innovation Review.

Mostert. S. & al. (2011) Effect of Corruption on Medical Care in Low-Income Countries. Pediatric Blood Cancer, DOI 10.1002/pbc.

Denburg et al. (2011) Pediatric Oncology Research in Low Income Countries: Ethical Concepts and Challenges. Pediatric Blood Cancer, DOI 10.1002/pbc.23419.

Jason Hwang and Clayton M. Christensen (2008) Disruptive Innovation In Health Care Delivery: A Framework For Business-Model Innovation. Health Affairs, Vol. 27, 5, 1329-1335.

Mainly based on previous work on Business Model innovation by C. Christensen, this article focuses on disruptive innovation for hospitals and general healthcare in the US (8 pages).

Regina E. Herzlinger (2006). Why Innovation In Health Care Is So Hard. Harvard Business Review.

An article on impediments to innovation in healthcare

Articles on new business models especially for social innovation or around social entrepreurship:

Kelly, M. : "Not Just for Profits", Strategy and Business magazine, spring 2009.

Boyd Cohen, Monika I. Winn (2007) Market imperfections, opportunity and sustainable entrepreneurship. Journal of Business Venturing 22, 29– 49.

Julie Battilana and Matthew Lee, "It Takes a Village to Raise an Entrepreneur". HBR Blog Network, May 24, 2012.

Julie Battilana and Matthew Lee discuss the recent growth of "hybrid" organizations that integrate aspects of business to address long-standing social problems, as well as the challenges faced by such organizations in regard to legal status, funding, customers and beneficiaries, and creating balanced organizational cultures. They call for the building of a "village" capable of incubating hybrid entrepreneurs - not only a new generation of hybrid entrepreneurs, but a new generation of employees, regulators, and consumers to support and grow along with these ventures.

Julie Battilana, Matthew Lee, John Walker, & Cheryl Dorsey. "In Search of the Hybrid Ideal". Stanford Social Innovation Review, Summer 2012

In the first large-scale, quantitative study of nascent social entrepreneurs, researchers from Harvard Business School and Echoing Green examine the rise of hybrid organizations that combine aspects of nonprofits and for-profits and the challenges hybrids face as they attempt to integrate traditionally separate organizational models.

Articles on business models and innovation in general:

David J. Teece (2010) Business Models, Business Strategy and Innovation. Long Range Planning 43, 172-194.

This is an economist's take on relationships among business models, strategy, and innovation, rather generalist, using several examples such as Netflix or Dell, a dense reading (23 pages).

Christoph Zott and Raphael Amit (2010). Business Model Design: An Activity System Perspective. Long Range Planning 43, 216-226.

Business models conceptualized as a system of interdependent activities, that companies can design with a purpose to both create value for the ecosystem and appropriate part of that value (11 pages)

Ramon Casadesus-Masanell and Jorge Tarzijan (2012). When One Business Model Isn't Enough. Harvard Business Review. January-February.

A practical example of a choice to compete with multiple business models in airline industry for LAN (6 pages)

Zhenya Lindgardt, Martin Reeves, Georges Stalk, and Michael S. Deimler (2009) Business Model Innovation: When the Game Gets Tough, Change the Game. Boston Consulting Group.

A consultant's take on business model innovation, with several interesting examples and another definition by BCG (9 pages)

Christoph Zott, Raphael Amit and Lorenzo Massa (2011).The Business Model: Recent Developments and Future Research. Journal of Management.

Literature review for further "academic" angle on the business model debate. Scholars do not always agree on what a business model is, and that the literature is developing largely in silos, according to the phenomena of interest to the respective researchers. (25 pages)

Call for Students Projects: Business Models for the Metronomics Global Health Initiative

Marc Le Menestrel — 2011-12-16T15:28:51Z

We are inviting students who are passionate about health and business to contribute to the development of new business models for cancer treatments in the developing world. Projects shall present a strategic analysis of the possibilities to reinvent our approach to anti-cancer strategies in countries where conventional therapies and business models are out of reach for economic, social, technological and/or ethical reasons.

Who we are

The Metronomics Global Health Initiative is a non-profit effort of scientists, medical associations, healthcare companies, international institutions and concerned citizens who act together to develop alternative anti-cancer strategies for children living in the developing world and beyond. Please visit our website for more information about our initiative: http://metronomics.newethicalbusiness.org .

Supervision

The projects will be supervised by Marc Le Menestrel (Associate Professor of Business at University Pompeu Fabra and Visiting Professor of Ethics, ISIC, INSEAD), Dr Nicolas André (Pediatric Oncologist, Department of Hematology & Pediatric Oncology, La Timone Hospital) and Dr Eddy Pasquier (Children's Cancer Institute Australia).

Context

We need new business models to meet the health needs of the poorest population of the world: as of today, 90% of the market addresses the needs of the 15% richest.On the other hand, 80% of all children live in developing countries and it is estimated that 200,000 of them are being affected by cancer each year. These children have very limited access to curative treatments and only about 25% will survive. In contrast, approximately 75% of the 50,000 children diagnosed with cancer each year in high-income countries will survive.

A series of problems prevent the development of efficient anti-cancer strategies in developing countries: availability of drugs and treatment facilities, cost and toxicities of treatment, distance to pediatric oncology units, compliance with treatment, delayed diagnosis, prior consultation of traditional practitioners and cultural barriers. Building up constraint-adapted, realistic therapeutic strategies for children suffering from cancer in these countries is therefore a must.

The Metronomic Global Health Initiative aims at developing innovative strategies that rely on: 1) the frequent oral administration of “old” anti-cancer drugs at low doses (metronomic chemotherapy); 2) the use of “old” non anti-cancer drugs for which anti-cancer properties have been unveiled (drug repositioning). These strategies allow developing a non-toxic, affordable and easy to administrate cancer treatment that is well suited for treating patients living
in developing countries.

Contact

Interested students shall contact Marc Le Menestrel to express their motivation and discuss specific topic, scheduling and following steps.

Overview of Possible Topics

Topic 1: Strategic analysis of anti-cancer treatments

General contextual presentation
Main industry actors
Main therapeutic approaches
Role of physicians
Governmental actors
Main recipients of therapies
Other strategic aspects.

Topic 2: New Business Models for Global Health in developing countries

Presentation of “Bottom of the pyramid” approaches in the health industry
New financing modes
New institutional actors
Generic drugs and product innovation
Social integration and modes of delivery
Other relevant aspects of Social Innovation.

Topic 3: Strategic analysis of Metronomic Anti-Cancer therapies in Developing Countries

The promises of Metronomics
Pediatric applications of Metronomics
The case of India
The case of China
The case of Africa

Click here to access our bibliography on New Business Models

Click here to access the corresponding Master class at the Barcelona GSE

Strategic analysis of Metronomic Anti-Cancer therapies in Developing Countries

Marc Le Menestrel — 2011-12-16T15:22:48Z

Students shall present an exploratory strategic analysis of Metronomic Anti-Cancer therapies in Developing Countries. Students are invited to use the concepts and methods used during the course without being constrained not to use any other relevant framework.

They may wish to consider the following aspects:

The promises of Metronomics

Pediatric applications of Metronomics

The case of India

The case of China

The case of Africa

Students are invited to draw explicit conclusions and recommendations from their analysis, specifying the specific aspects pertaining to developing countries.

Topic 1: Strategic analysis of anti-cancer treatments

Topic 2: New Business Models for Global Health in developing countries

Call for Students Projects: Business Models for the Metronomics Global Health Initiative

Click here to access our bibliography on New Business Models

Back to the session

Back to the course

New Business Models for Global Health in developing countries

Marc Le Menestrel — 2011-12-16T15:20:38Z

Students shall present an exploratory analysis of the current transformations of business models for Global Health in developing countries. Students are invited to use the concepts and methods used during the course without being constrained not to use any other relevant framework.

They may wish to consider the following aspects:

Presentation of “Bottom of the pyramid” approaches in the health industry

New financing modes
- This is a project started by Joao Rocha from the BSM Master in Business.

New institutional actors
- This is a project started by Cristin Fieber from the BSM Master in Business.

Generic drugs and product innovation

Social integration and modes of delivery

Other relevant aspects of Social Innovation.

Students are invited to draw explicit conclusions and recommendations from their analysis, specifying the specific aspects pertaining to developing countries.

Topic 1: Strategic analysis of anti-cancer treatments

Topic 3: Strategic analysis of Metronomic Anti-Cancer therapies in Developing Countries

Call for Students Projects: Business Models for the Metronomics Global Health Initiative

Click here to access our bibliography on New Business Models

Back to the session

Back to the course

Strategic analysis of anti-cancer treatments in developing countries

Marc Le Menestrel — 2011-12-16T15:16:11Z

Students shall present a strategic analysis of anti-cancer treatments worlwide indicating the specific aspects pertaining to developing countries. Students are invited to use the concepts and methods used during the course without being constrained not to use any other relevant framework.

They may wish to consider the following aspects:

Main industry actors

Main therapeutic approaches

Role of physicians

Governmental actors

Main recipients of therapies

Other strategic aspects

Students are invited to draw explicit conclusions and recommendations from their analysis, specifying the specific aspects pertaining to developing countries.

Proposed readings

Topic 2: New Business Models for Global Health in developing countries

Topic 3: Strategic analysis of Metronomic Anti-Cancer therapies in Developing Countries

Call for Students Projects: Business Models for the Metronomics Global Health Initiative

Click here to access our bibliography on New Business Models

Back to the session

Back to the course

The Nature of Scientific Evidence: Freedom and Precaution. June 1, 9:00-11:00

Marc Le Menestrel — 2011-11-21T07:15:47Z

This session explores ethical issues around the collection, analyze and use of scientific evidence in Health Management.

Questions treated in this session:

What is the objectivity of scientific evidence?

When do we listen to Early Warning Signals?

What are the roles of physicians, business and institutions in Health sciences?

Preparation

Browse through all the required readings, select one that you read carefully and identify the three main learning you obtained from it. Write them explicitly and share your reflections on the three questions above (max 500 words).

note that for the EEA report of 2002, you'll focus on 2 or 3 chapters of particular interest to you;
use the forum to indicate your choice

Required readings

Gee D. (2008) Establishing Evidence for Early Action: the Prevention of Reproductive and Developmental Harm. Basic & Clinical Pharmacology & Toxicology, 102, 257–266.

European Environment Agency (2002) Late lessons from early warnings: the precautionary principle 1896-2000. Issue Report n° 22.

European Environment Agency (2010) Pharmaceuticals in the environment. EEA Technical report No 1/2010.

Joy, B. (2000) Why the future doesn't need us. Our most powerful 21st-century technologies - robotics, genetic engineering, and nanotech - are threatening to make humans an endangered species. Wired - Issue 8.04.

Stirling, A. (2009) From Enlightenment to Enablement: opening up choices for innovation. Augusto López-Claros, ed., in The Innovation for Development Report: 2009-10 Basingstoke: Palgrave Macmillan pp. 199-210

Optional readings

Pollan, Michael (1998) Playing God in the Garden, The New York Times Magazine, October 25, 1998.

Oreskes N. a E. M. Conway (2010) Merchants of doubt. How a Handful of Scientists Obscured the Truth on Issues from Tobacco Smoke to Global Warming, Bloomsburry Press, New York.

Michaels, D. (2008) Doubt is their product. How Industry's Assault on Science Threatens Your Health. Oxford University Press, New York.

Rampton, S. and J. Stauber (2001) Trust us, we're experts! How industry manipulates science and gambles with your future. Tarcher Putnam, New York. See also Center for Media and Democracy.

Next Session

Back to the course

Alternative Ethical strategies for Global Health in Developing Countries. June 15, 9:00-11:00

Marc Le Menestrel — 2011-11-17T10:55:39Z

This session explores business strategies to improve health in developing countries using cheaper and more easily administrable products.

Questions treated in this session:

To whom is directed Global Health?

Are "bottom of the pyramid" business strategies more ethical?

Can business be part of more ethical solution to Global Health?

What is the ethics of future perspectives in Global Health?

Preparation

A paper of approximately 1000 words (per person) around the following question "Given your expertise, experience, learning in this Master and in this course, and also your knowledge of the Metronomics Global Health Initiative, what are the insights and/or recommendations you would like to share?"

See also the general call for Students' projects: Call for Students Projects: Business Models for the Metronomics Global Health Initiative where all the bibliographic material will be gathered.

Click here to access our bibliography on New Business Models for Global Health in Developing Countries

Back to the course

Global Health Institutions and Business Influence. June 8, 9:00-11:00

Marc Le Menestrel — 2011-11-17T10:44:05Z

This session analyzes why and how business actors may influence global health institutions and discusses to whom this may bring costs and benefits.

Questions treated in this session:

Should business influence Global Health institutions?

What are the strategic dilemmas faced by business actors in front of Global Health institutions?

What are the characteristics of influence tactics? What are the protection mechanisms?

What are the roles of business towards politics, science and society?

Preparation

Inspired by the required reading, analyze the extent to which the behavior of the tobacco industry can inform us about the behavior of the pharmaceutical industry. Choose a few similarities and differences and analyze them using the conceptual frameworks taught in class.

Required readings

World Health Organization. Tobacco Company Strategies to Undermine Tobacco Control Activities at the World Health Organization. Geneva: WHO, 2000. Executive Summary, pp. 1-21.

Optional readings

Hurt R.D., Robertson C.R.: “Prying Open the Door to the Tobacco Industry's Secrets About Nicotine, The Minnesota Tobacco Trial, JAMA ; October 7, 1998 – Vol. 280, N° 13.

Yach D. and Bettcher D.: “Globalization of Tobacco Marketing, Research and Industry Influence: Perspectives, trends and impacts on human welfare” Development, 1999, 42:4; 25–30.

Carter S.M.: “Mongoven, Biscoe & Duchin: destroying tobacco control activism from the inside”. Tobacco Control, 2002.

Next Session

Back to the course